5 min read
Therapeutic Thursday: How Do You Like Your Coffee — Hot, Cold Or In A Dessert?
Amgen is holding the line in cardiometabolic disease, confident in two major 2027 readouts despite the shadow of Novartis's Lp(a) failure. Novo is rebranding, reshuffling and hoping a new name and culture can do what investors think only M&A can.
